Literature DB >> 26407814

Are manufacturers sharing data as promised?

Evan Mayo-Wilson, Peter Doshi, Kay Dickersin.   

Abstract

Mesh：

Year:  2015        PMID： 26407814      PMCID： PMC6894486          DOI： 10.1136/bmj.h4169

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  Metabias: a challenge for comparative effectiveness research.

Authors:  Steven Goodman; Kay Dickersin
Journal:  Ann Intern Med       Date:  2011-07-05       Impact factor: 25.391

2.  Data sharing, year 1--access to data from industry-sponsored clinical trials.

Authors:  Brian L Strom; Marc Buyse; John Hughes; Bartha M Knoppers
Journal:  N Engl J Med       Date:  2014-10-15       Impact factor: 91.245

3.  Sharing clinical trial data: maximizing benefits, minimizing risk.

Authors:  Bernard Lo
Journal:  JAMA       Date:  2015-02-24       Impact factor: 56.272

4.  Sharing individual patient data from clinical trials.

Authors:  Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2015-01-15       Impact factor: 91.245

Review 5.  From promises to policies: is big pharma delivering on transparency?

Authors:  Peter Doshi
Journal:  BMJ       Date:  2014-02-26

6.  Increasing value and reducing waste: addressing inaccessible research.

Authors:  An-Wen Chan; Fujian Song; Andrew Vickers; Tom Jefferson; Kay Dickersin; Peter C Gøtzsche; Harlan M Krumholz; Davina Ghersi; H Bart van der Worp
Journal:  Lancet       Date:  2014-01-08       Impact factor: 79.321

Review 7.  Reanalyses of randomized clinical trial data.

Authors:  Shanil Ebrahim; Zahra N Sohani; Luis Montoya; Arnav Agarwal; Kristian Thorlund; Edward J Mills; John P A Ioannidis
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

8.  Preparing individual patient data from clinical trials for sharing: the GlaxoSmithKline approach.

Authors:  Sara Hughes; Karen Wells; Paul McSorley; Andrew Freeman
Journal:  Pharm Stat       Date:  2014-03-25       Impact factor: 1.894

9.  How to increase value and reduce waste when research priorities are set.

Authors:  Iain Chalmers; Michael B Bracken; Ben Djulbegovic; Silvio Garattini; Jonathan Grant; A Metin Gülmezoglu; David W Howells; John P A Ioannidis; Sandy Oliver
Journal:  Lancet       Date:  2014-01-08       Impact factor: 79.321

10.  Rationale for WHO's new position calling for prompt reporting and public disclosure of interventional clinical trial results.

Authors:  Vasee S Moorthy; Ghassan Karam; Kirsten S Vannice; Marie-Paule Kieny
Journal:  PLoS Med       Date:  2015-04-14       Impact factor: 11.069
View more
  9 in total

1.  Challenges and opportunities in accessing trial data: an example from statin primary prevention trials.

Authors:  Genevieve Umeh; Mark D Huffman
Journal:  Heart Asia       Date:  2017-04-13

Review 2.  Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review.

Authors:  Su Golder; Yoon K Loke; Kath Wright; Gill Norman
Journal:  PLoS Med       Date:  2016-09-20       Impact factor: 11.069

Review 3.  Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: systematic review.

Authors:  Sarah J Nevitt; Anthony G Marson; Becky Davie; Sally Reynolds; Lisa Williams; Catrin Tudur Smith
Journal:  BMJ       Date:  2017-04-05

4.  Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension.

Authors:  Paul Montgomery; Sean Grant; Evan Mayo-Wilson; Geraldine Macdonald; Susan Michie; Sally Hopewell; David Moher
Journal:  Trials       Date:  2018-07-31       Impact factor: 2.279

5.  Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events.

Authors:  Evan Mayo-Wilson; Nicole Fusco; Hwanhee Hong; Tianjing Li; Joseph K Canner; Kay Dickersin
Journal:  Trials       Date:  2019-09-05       Impact factor: 2.279

6.  Changes to aspects of ongoing randomised controlled trials with fixed designs.

Authors:  Xanthi Coskinas; John Simes; Manjula Schou; Andrew James Martin
Journal:  Trials       Date:  2020-06-03       Impact factor: 2.279

7.  Restoring invisible and abandoned trials of gabapentin for neuropathic pain: a clinical and methodological investigation.

Authors:  Evan Mayo-Wilson; Xiwei Chen; Riaz Qureshi; Stephanie Dickinson; Lilian Golzarri-Arroyo; Hwanhee Hong; Carsten Görg; Tianjing Li
Journal:  BMJ Open       Date:  2021-06-30       Impact factor: 2.692

8.  Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study).

Authors:  Evan Mayo-Wilson; Tianjing Li; Nicole Fusco; Kay Dickersin
Journal:  Res Synth Methods       Date:  2017-12-15       Impact factor: 5.273

9.  Caveat emptor: the combined effects of multiplicity and selective reporting.

Authors:  Tianjing Li; Evan Mayo-Wilson; Nicole Fusco; Hwanhee Hong; Kay Dickersin
Journal:  Trials       Date:  2018-09-17       Impact factor: 2.279
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.